Clearside Biomedical to Present Pivotal Phase 3 PEACHTREE Clinical Trial in Macular Edema Associated with Non-Infectious Uveitis

Source: Clearside Biomedical

Clearside Biomedical announced that data from PEACHTREE, its pivotal phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by Rahul N. Khurana, MD, an investigator for PEACHTREE, Partner at Northern California Retina Vitreous Associates, and Clinical Associate Professor in Ophthalmology at UCSF Medical Center, during a scientific session on Inflammation at the Retina Society 51st Annual Scientific Meeting in San Francisco, California. 

Dr. Khurana’s presentation, titled “Suprachoroidally Injected CLS-TA Improves Visual Acuity and Macular Edema in Non-infectious Uveitis: Results of the Phase 3 PEACHTREE Study,” is scheduled for Friday, September 14 at 3:55 pm Pacific Time.

“We expect to submit an NDA for suprachoroidal CLS-TA to treat macular edema associated with noninfectious uveitis to the FDA by the end of 2018,” Clearside’s Chief Executive Officer and President, Daniel H. White, said in a company news release. “Our confidence continues to grow in the potential of suprachoroidal CLS-TA, if approved, to become an important new treatment option for retinal and choroidal diseases like macular edema associated with noninfectious uveitis, and we are excited to share the PEACHTREE data with researchers and clinicians at this important forum.”

Related Content